Archive for July, 2009


In many cases the addict is the first family member to seek treatment. Other family members become involved in order to help the alcoholic get sober. Many family members refuse to consider the fact that they also have a problem that requires specialized treatment. These family members tend to deny their role in their addicted family and scapegoat personal and family problems upon the addicted person. They develop unrealistic expectations of how family life will improve with their loved one getting abstinent. When these expectations are not met, they blame the addict for the failure, even though he or she may be successfully following a recovery program. Their attitudes and behaviors can become such complicating factors in the addict’s recovery that they can contribute to the process of relapse and even “set-up” the addict’s next “episode of use.”

On the other hand family members can be powerful allies in helping the addict prevent fully engaging the relapse process. Relapse Prevention Planning utilizes the family’s motivation to get the addict sober. As family members become involved in relapse prevention planning, a strong focus is placed upon co-addiction and its role in the family relapse process. Family members are helped to recognize their own co-addiction and become actively involved in their own treatment. Addiction is a family disease that affects all family members, requiring everyone to get involved in treatment. The addict needs treatment for addiction. Other family members need treatment for co-addiction.
The term “co-addiction” is sometimes used to refer only to the spouse of an addict and other terms are used to refer to other family members. We are using the term “co-addict” to refer to ANYONE WHOSE LIFE HAS BECOME UNMANAGEABLE AS A RESULT OF LIVING IN A COMMITTED RELATIONSHIP WITH AN ADDICTED PERSON.

Co-addiction is a definable syndrome that is chronic and follows a predictable progression. When persons in a committed relationship with an addicted person attempt to control drinking, drug use, or addictive behavior (over which they are powerless), they lose control over their own behavior (over which they can have power) and their lives become unmanageable.

When you try to control
What you are powerless over
You lose control
Over what you can manage.

The person suffering from co-addiction develops physical, psychological, and social symptoms as a result of attempting to adapt to and compensate for the debilitating effects of the stress of living with someone who is addicted. As the co-addiction progresses, the stress-related symptoms become habitual. The symptoms also become self-reinforcing; that is, the presence of one symptom of co-addiction will automatically trigger other co-addiction symptoms. The co-addiction eventually becomes independent of the addiction that originally caused it. The symptoms of co-addiction will continue even if the addicted person in the family becomes sober or joins AA/NA, or the co-addict ends the relationship.

The condition of co-addiction manifests itself in three stages of progression.

Early Stage: Normal Problem Solving and Attempts to Adjust
The normal reaction within any family to pain, to crisis, and to the dysfunction of one member of the family is to do what they can to reduce the pain, ease the crisis, and to assist the dysfunctional member however possible in order to protect the family. These responses do not make things better when the problem is addiction, because these measures deprive the addicted person of the painful learning experiences that bring an awareness that his/her addiction is creating problems. At this stage, co-addiction is simply a reaction to the symptoms of addictive disease. It is a normal response to an abnormal situation.

Middle Stage: Habitual Self-Defeating Responses
When the culturally prescribed responses to stress and crisis do no bring relief from the pain created by the addiction in the family, the family members TRY HARDER. They do the same things, only more often, more intensely, mores desperately. They try to be more supportive, more helpful, more protective. They take on the responsibilities of the addicted person, not realizing that this causes the addict to become more irresponsible.
Things get worse instead of better and the sense of failure intensifies the response. Family members experience frustration, anxiety, and guilt. There is growing self-blame, lowering of self-concept, and self-defeating behaviors. They become isolated. They focus on the addict’s addictive behavior and their attempt to control it. They have little time to focus on anything else. As a result they often lose touch with the normal world outside of their family.

Chronic Stage: Family Collapse and Stress Degeneration
The continued habitual response to addiction in the family results in specific repetitive, circular patterns of self-defeating behavior. These behavior patterns are independent and self-reinforcing and will persist even in the absence of the symptoms of addictive disease.
The things the family members have done in a sincere effort to help have failed. The resulting despair and guilt bring about confusion and chaos and the inability to interrupt dysfunctional behavior even when they are aware that what they are doing is not helping. The thinking and behavior of the co-addict is OUT OF CONTROL, and these thinking and behavior patterns will continue independent of the addiction.
Co-addict degeneration is bio-psycho-social. The ineffective attempts to control drinking and drugging behavior elevate chronic stress to the point of producing stress-related physical illnesses such as migraine headaches, ulcers, and hypertension. This chronic stress may also result in a nervous breakdown or other emotional illnesses. Out-of-control behavior itself is an addiction-centered lifestyle that pervades all life activity, even that which seems unrelated to the addiction. Social degeneration occurs as the addiction focus interferes with relationships and social activity. Spiritual degeneration results, as the focus on the problem becomes so pervasive that there is no interest in anything beyond it, particularly concerns and need related to a higher meaning of life.
Recovery from co-addiction means learning to accept and detach from the symptoms of addiction. It means learning to manage and control the symptoms of co-addiction. It means learning to focus on personal needs and personal growth, learning to respect and like oneself. It means learning to choose appropriate behavior. It means learning to be in control of one’s own life.
Because it is a chronic condition, co-addiction, like addiction, is subject to relapse. But a condition of co-addict relapse may be more difficult to identify. Without an ongoing recovery program and proper care of oneself, old feelings and behaviors thought to be under control may surface and become out of control. Life again becomes unmanageable; the co-addict is in relapse mode.

RELAPSE WARNING SIGNS FOR CO-ADDICTION
From the observation of counselors who have worked with recovering family members, relapse warning signs for the co-addicted significant other have emerged. The following list has been compiled from these observations.

1.Situational Loss of Daily Structure. The family member’s daily routine is interrupted by a temporary situation such as illness, the children’s schedule, the holidays, vacation, etc. After the event or illness, the significant other does not return to all of the activities of his or her recovery program.

2.Lack of Personal Care. The significant other becomes careless about personal appearance and may stop doing and enjoying small things that are “just for own personal enjoyment.” The person returns to taking care of others first and self second or third.

3.Inability to Effectively Set and Maintain Limits. The significant other begins to experience behavioral problems with the children or roommates. Limits that are being set tend to be too lenient or too rigid and result in more discipline problems.

4.Loss of Constructive Planning. The significant other begins to feel confused and overwhelmed by personal responsibilities. Instead of deciding what is most important and doing that, he or she begins to react by doing the first thing that presents itself, while more important jobs go undone.

5.Indecision. The significant other becomes more and more unable to make decisions related to daily life.

6.Compulsive Behavior. The significant other experiences episodes during which he or she feels driven to do more. Whatever has already been done does not seem to be enough.

7.Fatigue or Lack of Rest. He or she becomes unable to sleep the number of hours necessary to feel rested. When sleep does occur, it is fitful.

8.Return of Unreasonable Resentments. The significant other finds himself or herself mentally reviewing persons or events that have hurt, angered, or been generally upsetting. As these are reviewed, the significant other relives the old emotions and feels resentments about them.

9.Return of the Tendency to Control People, Situations, and Things. As the co-addicted significant other feels less control over life, he or she begins openly to try to control and manipulate other people or situations. The addicted person may be the prime target, but does not necessarily have to be.

10.Defensiveness. The co-addicted person may not totally approve of some of his or her own actions, but when challenged about them will openly justify the actions in a sharp or angry way.

11.Self-Pity. The co-addict begins to dwell on problems from the present or the past and in turn begins to magnify them. The significant other person may ask, “Why does everything always happen to me?”

12.Overspending/Worrying about Money. The significant other may be very concerned about the family finances, yet impulsively spends money in order to “feel better.” He or she becomes convinced that what was purchased was deserved, but ends up feeling guilty and even more trapped.

13.Eating Disorder. The significant other “loses” his or her appetite to the point that even favorite foods are not appealing. Or the significant other may begin to overeat, regardless of appetite, in order to feel better. The overeating satisfies for only a very short time, or not at all.

14.Scapegoating. There is an increasing tendency to place the blame on other people, places, and things. The co-addict looks outside of self for the reasons why he or she is feeling bad.

15.Return of Fear and General Anxiety. The significant other begins to experience periods of time when he or she is nervous. Situations that previously did not cause fear or anxiety are now causing those emotions. The significant other may not even know the source of the nervousness.

16.Loss of Belief in a Higher Power. The significant other begins to lose belief in a higher power, whatever it may be. There is a tendency to rely more on self-alone, or to turn to the addict for strength and the solutions.

17.Attendance at Al-Anon Becomes Sporadic. The significant other changes the pattern of Al-Anon meeting attendance. He or she may go to fewer meetings, thinking there isn’t time, the meetings aren’t helping, or are not needed.

18.Mind Racing. The significant other feels as though he or she is on a treadmill that is going too fast. In spite of attempts to slow down, the mind continues to race with the many things that are undone or the problems that are unsolved.

19.Inability to Construct a Logical Chain of Thought. The significant other tries to solve problems and gets stuck on something that would normally be simple. It seems that his or her mind does not work anymore, that it is impossible to figure out the world. As a result, he or she feels powerless and frustrated with life.

20.Confusion. The significant other knows they are feeling out-of-sorts, but don’t know what is actually wrong.

21.Sleep Disturbance. Sleeplessness or fitful nights become more regular. The more the person tries to sleep, the less he or she is able to. Sleep may come, but it is not restful. The significant other looks tired in the morning instead of rested.

22.Artificial Emotion. The co-addict significant other begins to exhibit feelings without a conscious knowledge of why. He or she may become emotional for no reason at all.

23.Behavioral Loss of Control. The co-addict begins to lose control of his or her temper especially around the addict and/or the children or roommates. Loss of behavioral control is exhibited in such ways as over-punishing the children, hitting and yelling at the addict, or throwing things and tantrums.

24.Uncontrollable Mood Swings. Changes in the co-addict’s moods happen without any warning. The shifts are dramatic. He or she no longer feels somewhat down or somewhat happy, but instead goes from feeling extremely happy to extremely low.

25.Failure to Maintain Interpersonal (Informal) Support Systems. The co-addict stops reaching out to friends and family. This may happen very gradually. He or she turns down invitations for coffee, misses’ family gatherings, and no longer makes or returns phone calls.

26.Feelings of Loneliness and Isolation. The co-addict begins to spend more time alone. He or she usually rationalizes this behavior – too busy, the children, school, job, etc. Instead of dealing with the loneliness, the co-addict becomes more compulsive and impulsive. The isolation may be justified by convincing him or herself that no one understands or really cares.

27.Tunnel Vision. No matter what the issue or situation might be, the co-addict focuses in on his or her opinion or decision and is unable to see other points of view. He or she may become close-minded.

28.Return of Periods of Free Floating Anxiety and/or Panic Attacks. The co-addict may begin to re-experience, or experience for the first time, waves of anxiety that seem to occur for no specific reason. He or she may feel afraid and not know why. These uncontrollable feelings may snowballto the point that he or she is living in fear of fear.

29.Health Problems. Physical problems begin to occur such as headaches, migraines, stomach aches, chest pains, rashes, or allergies.

30.Use of Medication or Alcohol as a Means to Cope. Desperate to gain some kind of relief from the physical and/or emotional pain, the co-addict may begin to drink, use drugs, or take prescription medications. The alcohol or drug use provides temporary relief from the growing problems.

31.Total Abandonment of Support Meetings and Therapy Sessions. Due to a variety of reasons (belief that he or she no longer needs the meetings, immobilizing fear, resentment, etc.), the co-addict completely stops going to support meetings or to therapy or both.

32.Inability to change self-defeating behaviors. While there is recognition by the co-addict that what is being done is not good for himself or herself, there is still the compulsion to continue the behavior in spite of that knowledge.

33.Development of an “I Don’t Care” Attitude. It is easier to believe that “I don’t care” than it is to believe that “I am out of control.” In order to defend self-esteem, the co-addict rationalizes, “I don’t care.” As a result, a shift in value system occurs. Things that were once important now seem to be ignored.

34.Complete Loss of Daily Structure. The co-addict loses the belief that an orderly life is possible. He or she begins missing (forgetting) appointments or meetings, is unable to have scheduled meals, to go to bed or get up on time. The co-addict is unable to perform simple acts of daily function.

35.Despair and Suicidal Ideation. The co-addict begins to believe that the situation is hopeless. He or she feels that options are reduced to two or three choices: going insane, committing suicide, or numbing out with medication, and/or alcohol, drugs or maladaptive, perhaps compulsive behavior.

36.Major Physical Collapse. The physical symptoms become so severe that medical attention is required. These can be any of a number of symptoms that become so severe that they render the co-addict dysfunctional (e.g., an ulcer, migraines, heart pains, or heart palpitations).

37.Major Emotional Collapse. Having seemingly tried everything to cope, the co-addict can conceive no way to deal with his or her unmanageable life. At this point the co-addict may be so depressed, hostile, or anxious that he or she is completely out of control.

  • Share/Save/Bookmark

NIDAMED Helps Doctors Provide the Best in Medical Care

Washington, D.C. – The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, today unveiled its first comprehensive Physicians’ Outreach Initiative, NIDAMED, which gives medical professionals tools and resources to screen their patients for tobacco, alcohol, illicit, and nonmedical prescription drug use. The NIDAMED resources include an online screening tool, a companion quick reference guide, and a comprehensive resource guide for clinicians. The initiative stresses the importance of the patient-doctor relationship in identifying unhealthy behaviors before they evolve into life threatening conditions.

The NIDAMED tools – targeting primary care clinicians – were launched at a news conference at the National Press Club that featured NIDA Director Dr. Nora D. Volkow, Acting Director of the Office of National Drug Control Policy Ed Jurith, J.D., Sen. Carl Levin of Michigan, Acting Surgeon General Steven K. Galson, M.D., and representatives from the World Health Organization, the American Medical Association, and other organizations committed to helping patients who struggle with drug-related medical issues.

“Many patients do not discuss their drug use with their physicians, and do not receive treatment even when their drug abuse escalates,” said Dr. Volkow. “NIDAMED enables physicians to be the first line of defense against substance abuse and addiction and to increase awareness of the impact of substance use on a patient’s overall health.”

In 2007, an estimated 19.9 million Americans aged 12 or older (around 8 percent of the population) were current (past month) users of illegal drugs – nearly 1 in 5 of those 18 to 25 years old – and many more are current tobacco or binge alcohol users. The consequences of this drug use can be far-reaching – playing a role in the cause and progression of many medical disorders, including addiction. Yet only a fraction of people who need addiction treatment receive it.

“I have long worked with NIDA to increase access to effective treatment in the battle against addiction,” said Sen. Levin. “By encouraging physicians to consult with, screen and refer their patients who are in need of treatment, the NIDAMED initiative is a critical step towards achieving that goal. We must find ways to disseminate these important clinical tools, that can aid in mending lives and families, once torn asunder due to the scourge of addiction.”

The NIDAMED tools were developed because doctors are in a unique position to discuss drug-taking behaviors with their patients before they lead to serious medical problems. Research shows that screening, brief intervention, and referral to treatment by clinicians in general medical settings, can promote significant reductions in alcohol and tobacco use.

A growing body of literature also suggests potential reductions in illegal and nonmedical prescription drug use. Yet many primary care physicians express concern that they do not have the experience or diagnostic tools to identify drug use in their patients.

“Not only will these tools potentially help clinicians identify the use of drugs such as cocaine and heroin, they can also identify patients who are misusing prescription medications,” said Dr. Galson, a rear admiral in the U.S. Public Health Service. “In 2007, 16.3 million Americans age 12 and older had taken a prescription pain reliever, tranquilizer, stimulant, or sedative for nonmedical purposes at least once in the past year – behaviors that can lead to serious health problems, including addiction.”

“My doctor literally saved my life,” said Mink Rockmoore, a former Boston-area radio announcer who is a recovering heroin addict. “He worked hard to build my trust; he listened to my fears in a non-judgmental way; and he arranged for me to get both detox and treatment.”

NIDAMED’s screening tool was adapted from the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), developed, validated, and published by the World Health Organization (WHO) as an effective screening tool for identifying substance use. NIDA-modified ASSIST tools are specifically designed to fit into today’s busy clinical practices. Doctors can access the new tools at www.drugabuse.gov by clicking on the NIDAMED icon.

The online screening tool is an interactive Web site that guides clinicians through a short series of questions and, based on the patient’s responses, generates a substance involvement score that suggests the level of intervention needed. A physician can use this interactive tool during routine office visits. NIDAMED also includes an online resource guide with detailed instructions on how to implement the screening tool, discuss screening results, offer a brief intervention and make necessary referrals. In addition, a quick reference guide has been developed to serve as a prompt to medical professionals to initiate screening. This abbreviated guide provides a snapshot of the NIDA-modified ASSIST, briefly summarizing the questions, scoring and next steps.

Also included in the NIDAMED physician toolkit is a patient-tested postcard that encourages patients to “Tell Your Doctors About All the Drugs You Use” and offers Web links for further information. Doctors are encouraged to put the cards in their waiting rooms to be read by patients before their appointments.

NIDAMED was unveiled in conjunction with NIDA’s recently updated Principles of Drug Abuse Treatment: A Research Based Guide. This publication summarizes the 13 evidence-based principles of effective treatment, answers common questions, and describes types of treatment, providing examples of scientifically based and tested treatment components. The principles are based on three decades of scientific research and clinical practice that have yielded a variety of effective approaches to drug addiction treatment.

More information on all NIDAMED products and the Principles of Drug Abuse Treatment: A Research Based Guide can be found at www.drugabuse.gov/nidamed.



The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at www.drugabuse.gov. To order publications in English or Spanish, call NIDA’s new DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov.

The National Institutes of Health (NIH) – The Nation’s Medical Research Agency – includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


For more information about any item in this Release Contact:

Download PDF [104 KB]


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Wednesday, May 13, 2009. The U.S. government's official web portal
  • Share/Save/Bookmark
According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) National Survey on Drug Use and Health in 2006, 23.6 million persons aged 12 or older needed treatment for an illicit drug or alcohol abuse problem (9.6 percent of the persons aged 12 or older). Of these, only 2.5 million—10.8 percent of those who needed treatment—received it at a specialty facility.

SAMHSA also reports characteristics of admissions and discharges from substance abuse treatment facilities in their Treatment Episode Data Set (TEDS). According to TEDS, in 2006 there were nearly 1.8 million admissions for treatment of alcohol and drug abuse to facilities that report to State administrative data systems.1,2 Most admissions (40 percent) were for alcohol treatment. Heroin and other opiates accounted for the largest percentage of drug-related admissions (18 percent), followed by marijuana (16 percent).

By Drug: Admissions to Publicly Funded
Substance Abuse Treatment Programs, 2006


Percentage
of Admissions*
Substance
or Drug
21.9 Alcohol
17.8 Alcohol + another drug
16.1 Marijuana
13.7 Heroin
9.9 Smoked cocaine (crack)
8.7 Stimulants
4.2 Opiates (not heroin) **
4.0 Other-than-smoked cocaine (e.g., cocaine powder)
0.4 Tranquilizers
0.2 PCP
0.2 Sedatives
0.1 Hallucinogens
0.1 Inhalants
0.5 Other drugs
2.4 None reported

About 59 percent of admissions were White, 21 percent were African-American, and 14 percent were Hispanic or Latino. Another 2.3 percent were Alaska Native or American Indian and 1 percent were Asian/Pacific Islander. The remaining 2 percent fell into the “Other” category.

By Race: Admissions to Publicly Funded
Substance Abuse Treatment Programs, 2006

Percentage
of Admissions
Race/Ethinicity
59.4 White
21.3 African-American
14.0 Hispanic Origin
2.3 American Indian or Alaska Native
1.0 Asian/Pacific Islander
2.0 Other

The majority of patients entering treatment were 20–24 years old (14.4 percent), followed by those 25 to 29 (14 percent) and 40 to 44 (13.9 percent).

By Age Group: Admissions to Publicly Funded
Substance Abuse Treatment Programs, 2006


Percentage
of Admissions
Age Group
14.4 20 – 24
14.0 25 – 29
13.9 40 – 44
13.1 35 – 39
11.3 30 – 34
11.1 45 – 49
10.4 15 – 19
9.0 50 – 59
1.3 younger than 15
1.0 60 – 64
0.6 65 or older

For other information on treatment trends, visit the Substance Abuse and Mental Health Services Administration, Office of Applied Studies Web site at www.oas.samhsa.gov or visit the National Clearinghouse for Alcohol and Drug Information at www.health.org.

For information on treatment research findings, visit the NIDA web site at www.nida.nih.gov/DrugPages/Treatment.html.



1 Includes facilities that are licensed or certified by the State substance abuse agency to provide substance abuse treatment. In general, facilities that report data are those that receive State alcohol and/or drug agency funds for the provision of alcohol and/or drug treatment services.

2 Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights – 2006. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-40, DHHS Publication No. (SMA) 08-4313, Rockville, MD.


* May add up to more than 100 percent because of rounding.

** These drugs include codeine, hydrocodone, hydromorphone, meperidine, morphine, opium, oxycodone, pentazocine, propoxyphene, tramadol, and any other drug with morphine-like effects. Non-prescription use of methadone is not included.

Revised 6/08 This page has been accessed 1207581times since 11/5/99.

Recommended Reading

Other NIDA Web Sites


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Wednesday, May 6, 2009. The U.S. government's official web portal
  • Share/Save/Bookmark
Director’s Column
Vol. 17, No. 3 (October 2002)



By Glen R. Hanson, Ph.D., D.D.S., NIDA Acting Director

NIDA Acting Director, Glen R. Hanson

Drug addiction is a chronic relapsing disorder. As when patients in treatment for hypertension or asthma temporarily lose control, relapse to drug abuse does not mean treatment does not work, or the patient is not making an effort, or he or she will never have a productive life with long-term freedom from disease. Nevertheless, relapse is perhaps the most frustrating and demoralizing feature of drug addiction, for those who have it and those who would help them.

Clinical observation and research tell us that three types of stimulus can trigger intense drug craving, leading to renewed abuse:

  • Priming: “Just one” exposure to the formerly abused substance — be it a cigarette, a drink, or an illegal drug — can precipitate rapid resumption of abuse at previously established levels or greater.
  • Environmental cues (people, places, or things associated with past drug use): One vivid illustration of the power of such cues is a negative one: A small percentage of American service personnel became addicted to heroin while overseas during the Vietnam War. When they were removed from that environment, the great majority, after detoxification, reported no further problems with opiates.
  • Stress: Both acute and chronic stress can contribute to the establishment, maintenance, and resumption of drug abuse. Patients and treatment providers alike point to stress as the most common cause of relapse. The impact of stress recently was highlighted when researchers documented increased rates of smoking and alcohol consumption by New Yorkers after the September 11, 2001, attacks.

Our knowledge of relapse is incorporated in science-based drug treatments. In cognitive-behavioral therapy, for example, patients learn to confront the consequences of their drug use, recognize the environmental cues and potentially stressful situations that trigger strong drug cravings, and develop strategies to steer clear or respond without relapsing. Recent research has shown that patients who benefit from cognitive-behavioral therapy may even show further improvement after treatment has ended and with passing time.

New research findings appear to shed light on one of the deepest mysteries involving drug relapse: What accounts for the extraordinary persistence of drug cravings?

Science-based medical treatments buffer patients against the craving that leads to relapse. Methadone and other opioid agonist agents block the euphoric effects of opioids and stabilize brain processes whose disruption is linked to craving. Naltrexone, an opioid antagonist, blocks opioid-induced euphoria and counters opioid craving with an aversive effect. Disulfiram (Antabuse) is used to treat alcohol abuse, and it is currently being tested to determine whether it also can offset cocaine craving. Antianxiety agents are prescribed to moderate stress.

New research findings appear to shed light on one of the deepest mysteries involving drug relapse: We know that former abusers of addictive drugs remain vulnerable to powerful drug cravings for months or years after establishing abstinence. What accounts for the extraordinary persistence of drug cravings?

Scientists have known for some time that addictive drugs hyperactivate key brain circuits that provide pleasure and are closely linked to motivation and memory. Research also has shown that drugs change brain cells in these circuits in numerous ways, some of which might be linked to craving. However, these changes generally last only as long as a drug is actually present, or a little longer. To explain how craving can recur after long abstinence, researchers need to show that the drugs change the cells in ways that change back slowly or not at all.

The natural place to look for long-lasting drug-induced alterations is in the same circuits that produce short-term effects. Key cells in these circuits are located in an area called the midbrain; they manufacture a chemical called dopamine and release it in a nearby area called the nucleus accumbens, where it produces powerful mood effects.

During the past 3 years, research teams at Yale and Texas Southwestern Universities demonstrated that repeated exposure to cocaine produces alterations in gene activity in the nucleus accumbens that can persist for weeks. Last year, researchers at the University of Michigan showed that cocaine self-administration changes the actual shape of these neurons — a change that is long-lasting or even permanent. Moreover, its specific nature — a proliferation of signal receptors — might be expected to contribute to craving by heightening the cells’ general reactivity.

Further research will tell whether these changes are critically important to long-term vulnerability to drug craving, or whether they play a relatively minor role. The studies were conducted with laboratory animals and cocaine, and we need to find out whether they also apply in humans and with other drugs. Although uncertainties remain, these new results provide powerful confirmation of the neurobiological and chronic nature of drug addiction, evidenced at still more fundamental levels of brain cell operation. The studies also demonstrate the power of new neuroscience tools to elucidate the underlying causes of drug abuse. Ultimately, we need approaches this powerful to gain the understanding necessary to solve the mysteries of craving and generate treatments that help all patients move beyond the reach of relapse.

Volume 17, Number 3 (October 2002)

NIDA Notes graphic

Search NIDA Notes

About NIDA Notes

Free Subscription
to NIDA Notes

Volumes:

For additional information about NIDA Notes, send e-mail to Information@nida.nih.gov


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Monday, June 4, 2007. The U.S. government's official web portal
  • Share/Save/Bookmark

Pursuing New Medications

NIDA Home > Publications > NIDA Notes > Vol. 19, No. 1 > Special Supplement
Developing Effective Addiction Treatments
Special Supplement
Vol. 19, No. 1 (April 2004)


Researcher

In recent years, people from all walks of life have sought treatment for addiction to powerful narcotic pain-relieving medications, such as OxyContin and Vicodin, that they have abused outside of a medical regimen. These medications share many properties with heroin, which currently ensnares more than a million people nationwide in the web of addiction. Those who become addicted to legal painkillers or street opiates now have a new medication to help them reclaim their lives. Approved by FDA in 2002, buprenorphine joins two other approved opiate treatment medications–methadone, used in long-term treatment, and the NIDA-developed opiate blocker naltrexone, used to help patients remain drug-free after they have stopped using opiates.

Buprenorphine is the first medication for opiate addiction treatment that can be prescribed by private physicians in offices and clinics. Use of this medication in mainstream medicine should help reduce the stigma still associated with drug abuse treatment, while encouraging more patients to seek treatment for addiction to heroin and other opiates. NIDA also is pursuing medications for cocaine and methamphetamine abuse and addiction, for which no medications are yet available. To fill this void, the Institute is applying the same scientific medications development methodologies that put effective opiate treatment medications into the hands of clinicians and their patients.

Researcher

On one research track, clinical researchers are screening medications previously approved to treat other disorders. In these small-scale trials, several agents have appeared to weaken the addictive cycle of drug-craving, drug-seeking, and drug-taking. Among them are amantadine (currently used for Parkinson’s disease), disulfiram (Antabuse), baclofen (an antispasticity agent), tiagabine and topiramate (antiepileptics), and modafinil (used in narcolepsy). Disulfiram and naltrexone, both effective in treating alcoholism, may fill a critical need for medications that can help cocaine-abusing individuals who also abuse alcohol. Propranolol, a medication used to lower blood pressure, may help substance abuse patients stay the course during the critical early days of treatment, by alleviating their unpleasant withdrawal symptoms. Researchers are now conducting larger, longer studies to confirm these encouraging results. Because the medications work by a variety of different mechanisms, some of which may complement each other, researchers also will examine whether they may be more effective in combination than alone. Some may also work optimally with specific behavioral therapies.

On another track, researchers in NIDA’s cocaine and methamphetamine treatment discovery programs are working to identify new chemical compounds whose pharmacological actions modulate the effects of psychostimulants on the brain and behavior. They already have shown that one compound that blocks a brain cannabinoid receptor can prevent animals from reinitiating cocaine use after exposure to drug-related cues and stressful events. Other compounds that curb the drug-induced flooding of the brain’s reward pathways with dopamine may be able to treat addiction to all abused drugs. Still other compounds counter psychostimulants’ ability to activate receptor molecules, nerve networks, and neurochemical mechanisms to create pleasure and craving.

NIDA Art CardNIDA uses art cards, displayed in restaurants and other public places, to warn smokers that nicotine, like other drugs, can be addictive.

Another NIDA initiative is focusing on new medications for treating nicotine addiction. Launched in the 1970s, NIDA’s basic research in this area provided the scientific basis for nicotine replacement therapies, such as the transdermal patch, that today help many patients overcome nicotine dependence. The Institute is now pursuing several approaches to medications that could intercept and neutralize nicotine, cocaine, and methamphetamine in the bloodstream before they can act in the brain. In one approach, vaccines containing the abused substance are linked with a larger carrier molecule and stimulate the body to produce antibodies to the drug. Another approach enhances the rate at which the body’s enzymes break down the drug molecules into inactive byproducts.

Identifying Effective Behavioral Therapies

Therapies that help drug abuse patients overcome erroneous thought patterns and behaviors that reinforce their abuse and addiction are critical in treating drug abuse and preventing its harmful consequences. Cognitive-behavioral therapies can stand alone as front-line interventions that help many patients stop using drugs and remain drug-free. And they can increase the effectiveness of treatment medications by boosting patients’ motivation to remain in treatment, take their medication as scheduled, and learn strategies to avoid relapse and lead drug-free lives. NIDA-supported research has demonstrated that combining medications, as available, with behavioral treatments is the best way to enhance success for most patients.

Man sitting on a couch

Over the last decade, NIDA’s Behavioral Therapies Development Program established a three-stage process to develop and introduce new behavioral approaches into clinical practice, similar to that required by the Food and Drug Administration to establish the safety and efficacy of medications. Building on research that suggests avenues for developing new therapies or refining existing ones, pilot studies explore the potential of each new or refined treatment. Those showing promise are then tested in research settings in small- and large-scale clinical trials. Finally, clinical trials can be done in community settings for those therapies that demonstrate therapeutic efficacy.

NIDA behavioral therapy researchers have designed several cognitive-behavioral therapies to help methamphetamine abusers. One innovative therapy gives patients a voucher each time they submit a drug-free urine sample. Vouchers may be exchanged for goods or services that provide pleasurable, legal alternatives to drug use or, as in methadone treatment programs, for special privileges, like reducing the number of required visits to a treatment clinic. Studies show that providing vouchers for drug-free urine tests can help patients stop cocaine and methamphetamine use and remain abstinent for extended periods. Variations of voucher-based therapies that use lower cost vouchers or involve family and other community resources in treatment can be matched to the resources of treatment programs and needs of cocaine-addicted individuals.

Ethnic FamilyFamily therapies tailored to the ethnicity or race of substance-abusing teens have proven successful.

In the last 10 years, behavioral treatments have demonstrated their potency in improving the health of diverse individuals with many types of drug abuse and other mental disorders. Proven treatments include individual cognitive-behavioral therapy, family therapies for Hispanic and African-American adolescent substance abusers, combination behavioral and medication therapies for adult smokers, and couples therapy for opiate-addicted men and women in methadone treatment programs. The benefits of many of these treatments endure long after treatment has ended. And with individual cognitive-behavioral therapy, the benefits appear to increase over time.

Volume 19, Number 1 (April 2004)

NIDA Notes graphic

Search NIDA Notes

About NIDA Notes

Free Subscription
to NIDA Notes

Volumes:

For additional information about NIDA Notes, send e-mail to Information@nida.nih.gov


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Friday, May 19, 2006. The U.S. government's official web portal
  • Share/Save/Bookmark

Screening is a preliminary evaluation that attempts to determine whether key features of drug abuse are present in an individual. Screening indicates whether the problem of drug abuse is likely to be present.

Assessment is a thorough evaluation designed to definitively establish the presence or absence of a diagnosable drug abuse problem. The results of the assessment also suggest what is likely to be the most appropriate type of treatment when drug problems are evident.

Why are screening and assessments necessary?

The aim of screening is to identify as many potential or actual abusers as early in their use or abuse history as possible so appropriate intervention services can be provided. Thus, the process is twofold. Individuals are screened to identify the potential presence of an alcohol- or drug-related problem, while the assessment stage takes the process a step further and confirms the existence of a problem, identifies the nature of the problem(s), and suggests appropriate avenues of treatment.

Who is qualified to screen and assess?

Clinicians, counselors, family physicians, coworkers, families, friends, and even addicts themselves can do screenings. This initial step, as mentioned above, identifies a person as a possible drug abuser. It is important to recognize the importance of this step. For drug abusers, screening is often the first step toward recovery. To that end, professionals, as opposed to untrained individuals, may be the best individuals to conduct such evaluations.
When the screening indicates a likely problem, a clinician, counselor, or family physician will want to use a diagnostic interview to determine whether and to what extent the individual’s drug use satisfies established criteria for abuse.

How are such assessments performed?

There are two types of interviews that can be utilized during the assessment phase – structured and semi-structured. Structured interviews provide a prearranged sequence of questions that permit untrained individuals to assess reliably. Semi-structured interviews are designed to guide trained mental health professionals in conducting detailed examinations of patients. Although structured interviews yield reliable diagnoses, they do not provide as much information for treatment planning as do semi-structured interviews, which rely more heavily on the interviewer’s expertise and professional training and experience.

Are there any techniques to get the individual to embrace the concept of treatment?

Aside from court mandated treatment, with which the addict is given little choice, a number of approaches can work, depending on the individual. Interventions, for example, in which loved ones confront the addict with their personal concerns and fears is often a powerful way to shock addicts into treatment. The decision to seek or not to seek, however, treatment is ultimately up to the individual addict.

Can I tell if someone is abusing alcohol or other drugs?

It is very difficult to identify alcoholics or drug addicts, sober or intoxicated, just by watching and talking to them. When they are sober, drug abusers tend to behave very similar to non-abusers, especially if they are young or at the beginning of their abuse. Moreover, just because someone has had too much to drink or has ingested an intoxicating drug is no guarantee that he or she is an alcoholic or drug addict.

What tools are available to screen for alcohol or drug abuse?

The two most widely used self-report screening instruments for alcoholism are the 4-item CAGE and the 25-item Michigan Alcoholism Screening Test (MAST). Both the CAGE and the MAST solicit Yes-No responses to questions about common consequences of alcohol misuse. The CAGE asks the following: “Have you ever: 1) attempted to Cut back on alcohol? 2) been Annoyed by comments made about your drinking? 3) felt Guilty about drinking? 4) had an Eye-opener first thing in the morning to steady your nerves? These instruments are widely used because they combine brevity with sensitivity, although they are of limited usefulness with persons who do not want their abusive drinking known.

The Alcohol Use Inventory (AUI) is another widely used screening instrument for adults suspected of problem drinking. The AUI is a self-report instrument designed to assess 24 different behaviors, feelings, and attitudes associated with the use and abuse of alcohol. Because the instrument focuses on problematic drinking, it is not suitable for persons who are unable or unwilling to acknowledge existing drinking problems.

The Substance Abuse Subtle Screening Inventory (SASSI) is used to identify alcohol and drug abusers and differentiate them from social drinkers and general psychiatric clients. The SASSI is a single-page questionnaire. On one side are 52 True-False questions that seem to be unrelated to chemical abuse. On the other side are the Risk Prediction Scales that allow clients to self-report on 12 alcohol-related and 14 drug-related items. The SASSI’s ease of administration and scoring, its clear suggestions for interpretation, and the informative and carefully written manual make it very attractive for practitioners, such as individuals with Employee Assistance Programs (EAPs).

What tools are available to assess for alcohol or drug abuse?

The Addiction Severity Index (ASI) is the most widely used measure of problem severity among addicted clients entering treatment. This interview was developed to serve as a standardized and reliable instrument for evaluating drug-abusing clients. The interview is used frequently in both traditional research settings and as an outcome measure in clinical settings. It has been expanded to specialized populations, such as cocaine-abusing mothers, opiate-dependent people, federal prisoners, and homeless people.

The ASI covers the client’s medical status, employment and support status, drug use, alcohol use, legal status, family and social relationships, and psychiatric status. Clients are asked to respond to specific questions about the problems they have experienced, both within the past 30 days and over their lifetimes. Thus, both urgent and chronic concerns are identified by ASI. Client answers to the ASI inquiries are summarized into composite scores and are used to measure changes over time in response to treatment.

In addition to these client-based ratings, the interviewer makes an independent rating of the severity of each problem area, on the basis of the interviewer’s experience with the client during the interview. This rating starts at 0 (no problem exists) and ends at 9 (an extreme problem exists and treatment is absolutely necessary).

The Diagnostic Interview Schedule-IV (DIS-IV), an interview based on the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), is the most widely used structured diagnostic interview. The DIS offers diagnoses on a variety of disorders, including schizophrenia, pathological gambling, and alcohol and drug dependence. The DIS remains the leading interview for the diagnosis of disorders by individuals untrained in the discipline of psychiatry.

What factors should be considered when deciding on the most appropriate instrument?

  • Ease of use
  • Expertise and time required of staff to administer and score test
  • Possibility of bias (cultural or administrative)
  • Validity (does it measure what it is intended to measure?) and reliability (do re-tests yield identical results?)
  • Credibility of test among academic and treatment professionals
  • Adaptation of test to management information system (MIS) input and retrieval
  • Availability in languages other than English
  • Motivation level and verbal and reading skills required of persons to be assessed
  • Average cost per test

How appropriate are these tools for workplace settings?

There are tools appropriate for the workplace. Given the non-clinical setting, the desire to get accurate results quickly, and the likelihood that employees will not be willing to admit to their alcohol and/or drug use habits, the most appropriate tool is the Substance Abuse Subtle Screening Inventory (SASSI). As mentioned above, its length and ease of administration is ideal for employers or other individuals charged with managing EAPs.

What are the capabilities of drug testing?

Drug testing, such as through urinalysis, provides an objective or impartial measure of drug use. This objective measure stands in contrast to self-report measures of drug use, in which individuals are asked to describe subjectively their alcohol- or drug-using behaviors. Research has consistently documented that objective measures of drug use are more reliable indicators of actual drug use than self-report measures. Simply put, individuals are naturally inclined to hide embarrassing behaviors when given the chance to do so. Drug tests greatly reduce the likelihood of hiding recent drug-using behaviors.
Drug tests, like urinalysis, detect the presence of most drugs within 72 hours of use. After this window has passed, most drugs become undetectable. The exception is marijuana, which can be detected in urine for up to 30 days. Most drug tests cannot, however, identify historical use or drug dependence. Drug tests can only stipulate whether an individual has used a particular drug recently.


U.S. Department of Labor, Frances Perkins Building, 200 Constitution Ave., NW, Washington, DC 20210

Phone Numbers

www.dol.gov | Telephone: 1-866-4-USA-DOL (1-866-487-2365) | TTY: 1-877-889-5627 Contact Us
  • Share/Save/Bookmark

Commonly Abused Drugs

Substances:
Category and Name
Examples of Commercial
and Street Names
DEA Schedule*/
How Administered**
Intoxication Effects/Potential Health Consequences
Cannabinoids euphoria, slowed thinking and reaction time, confusion, impaired balance and coordination/cough, frequent respiratory infections; impaired memory and learning; increased heart rate, anxiety; panic attacks; tolerance, addiction
hashish boom, chronic, gangster, hash, hash oil, hemp I/swallowed, smoked
marijuana blunt, dope, ganja, grass, herb, joints, Mary Jane, pot, reefer, sinsemilla, skunk, weed I/swallowed, smoked
Depressants reduced anxiety; feeling of well-being; lowered inhibitions; slowed pulse and breathing; lowered blood pressure; poor concentration/fatigue; confusion; impaired coordination, memory, judgment; addiction; respiratory depression and arrest; death

Also, for barbiturates—sedation, drowsiness/depression, unusual excitement, fever, irritability, poor judgment, slurred speech, dizziness, life-threatening withdrawal

for benzodiazepines—sedation, drowsiness/dizziness

for flunitrazepam—visual and gastrointestinal disturbances, urinary retention, memory loss for the time under the drug’s effects

for GHB—drowsiness, nausea/vomiting, headache, loss of consciousness, loss of reflexes, seizures, coma, death

for methaqualone—euphoria/depression, poor reflexes, slurred speech, coma

barbiturates Amytal, Nembutal, Seconal, Phenobarbital: barbs, reds, red birds, phennies, tooies, yellows, yellow jackets II, III, V/injected, swallowed
benzodiazepines (other than flunitrazepam) Ativan, Halcion, Librium, Valium, Xanax: candy, downers, sleeping pills, tranks IV/swallowed, injected
flunitrazepam*** Rohypnol: forget-me pill, Mexican Valium, R2, Roche, roofies, roofinol, rope, rophies IV/swallowed, snorted
GHB*** gamma-
hydroxybutyrate:
G, Georgia home boy, grievous bodily harm, liquid ecstasy
I/swallowed
methaqualone Quaalude, Sopor, Parest: ludes, mandrex, quad, quay I/injected, swallowed
Dissociative Anesthetics increased heart rate and blood pressure, impaired motor function/memory loss; numbness; nausea/vomiting

Also, for ketamine—at high doses, delirium, depression, respiratory depression and arrest

for PCP and analogs—possible decrease in blood pressure and heart rate, panic, aggression, violence/loss of appetite, depression

ketamine Ketalar SV: cat Valiums, K, Special K, vitamin K III/injected, snorted, smoked
PCP and analogs phencyclidine; angel dust, boat, hog, love boat, peace pill I, II/injected, swallowed, smoked
Hallucinogens altered states of perception and feeling; nausea; persisting perception disorder (flashbacks)

Also, Also for LSD and mescaline—increased body temperature, heart rate, blood pressure; loss of appetite, sleeplessness, numbness, weakness, tremors

for for LSD—persistent mental disorders

for for psilocybin—nervousness, paranoia

LSD lysergic acid diethylamide: acid, blotter, boomers, cubes, microdot, yellow sunshines I/swallowed, absorbed through mouth tissues
mescaline buttons, cactus, mesc, peyote I/swallowed, smoked
psilocybin magic mushroom, purple passion, shrooms I/swallowed
Opioids and Morphine Derivatives pain relief, euphoria, drowsiness/nausea, constipation, confusion, sedation, respiratory depression and arrest, tolerance, addiction, unconsciousness, coma, death

Also, for codeine—less analgesia, sedation, and respiratory depression than morphine

for heroin—staggering gait

codeine Empirin with Codeine, Fiorinal with Codeine, Robitussin A-C, Tylenol with Codeine: Captain Cody, schoolboy; (with glutethimide) doors & fours, loads, pancakes and syrup II, III, IV, V/injected, swallowed
fentanyl and fentanyl analogs Actiq, Duragesic, Sublimaze: Apache, China girl, China white, dance fever, friend, goodfella, jackpot, murder 8, TNT, Tango and Cash I, II/injected, smoked, snorted
heroin diacetyl-
morphine:
brown sugar, dope, H, horse, junk, skag, skunk, smack, white horse
I/injected, smoked, snorted
morphine Roxanol, Duramorph: M, Miss Emma, monkey, white stuff II, III/injected, swallowed, smoked
opium laudanum, paregoric: big O, black stuff, block, gum, hop II, III, V/swallowed, smoked
oxycodone HCL Oxycontin: Oxy, O.C., killer II/swallowed, snorted, injected
hydrocodone bitartrate, acetaminophen Vicodin: vike, Watson-387 II/swallowed
Stimulants increased heart rate, blood pressure, metabolism; feelings of exhilaration, energy, increased mental alertness/rapid or irregular heart beat; reduced appetite, weight loss, heart failure, nervousness, insomnia

Also, for amphetamine—rapid breathing/tremor, loss of coordination; irritability, anxiousness, restlessness, delirium, panic, paranoia, impulsive behavior, aggressiveness, tolerance, addiction, psychosis

for cocaine—increased temperature/chest pain, respiratory failure, nausea, abdominal pain, strokes, seizures, headaches, malnutrition, panic attacks

for MDMA—mild hallucinogenic effects, increased tactile sensitivity, empathic feelings/impaired memory and learning, hyperthermia, cardiac toxicity, renal failure, liver toxicity

for methamphetamine—aggression, violence, psychotic behavior/memory loss, cardiac and neurological damage; impaired memory and learning, tolerance, addiction

for nicotine—additional effects attributable to tobacco exposure; adverse pregnancy outcomes; chronic lung disease, cardiovascular disease, stroke, cancer, tolerance, addiction

amphetamine Biphetamine, Dexedrine: bennies, black beauties, crosses, hearts, LA turnaround, speed, truck drivers, uppers II/injected, swallowed, smoked, snorted
cocaine Cocaine hydrochloride: blow, bump, C, candy, Charlie, coke, crack, flake, rock, snow, toot II/injected, smoked, snorted
MDMA (methylenedioxy-
methamphetamine)
Adam, clarity, ecstasy, Eve, lover’s speed, peace, STP, X, XTC I/swallowed
methamphetamine Desoxyn: chalk, crank, crystal, fire, glass, go fast, ice, meth, speed II/injected, swallowed, smoked, snorted
methylphenidate (safe and effective for treatment of ADHD) Ritalin: JIF, MPH, R-ball, Skippy, the smart drug, vitamin R II/injected, swallowed, snorted
nicotine cigarettes, cigars, smokeless tobacco, snuff, spit tobacco, bidis, chew not scheduled/smoked, snorted, taken in snuff and spit tobacco
Other Compounds
anabolic steroids Anadrol, Oxandrin, Durabolin, Depo-
Testosterone, Equipoise:
roids, juice
III/injected, swallowed, applied to skin no intoxication effects/hypertension, blood clotting and cholesterol changes, liver cysts and cancer, kidney cancer, hostility and aggression, acne; in adolescents, premature stoppage of growth; in males, prostate cancer, reduced sperm production, shrunken testicles, breast enlargement; in females, menstrual irregularities, development of beard and other masculine characteristics
Dextromethorphan (DXM) Found in some cough and cold medications; Robotripping, Robo, Triple C not scheduled/swallowed Dissociative effects, distorted visual perceptions to complete dissociative effects/for effects at higher doses see ‘dissociative anesthetics’
inhalants Solvents (paint thinners, gasoline, glues), gases (butane, propane, aerosol propellants, nitrous oxide), nitrites (isoamyl, isobutyl, cyclohexyl): laughing gas, poppers, snappers, whippets not scheduled/inhaled through nose or mouth stimulation, loss of inhibition; headache; nausea or vomiting; slurred speech, loss of motor coordination; wheezing/unconsciousness, cramps, weight loss, muscle weakness, depression, memory impairment, damage to cardiovascular and nervous systems, sudden death


* Schedule I and II drugs have a high potential for abuse. They require greater storage security and have a quota on manufacturing, among other restrictions. Schedule I drugs are available for research only and have no approved medical use; Schedule II drugs are available only by prescription (unrefillable) and require a form for ordering. Schedule III and IV drugs are available by prescription, may have five refills in 6 months, and may be ordered orally. Some Schedule V drugs are available over the counter.


** Taking drugs by injection can increase the risk of infection through needle contamination with staphylococci, HIV, hepatitis, and other organisms.


*** Associated with sexual assaults.



Principles of Drug Addiction Treatment

More than three decades of scientific research have yielded 13 fundamental principles that characterize effective drug abuse treatment. These principles are detailed in NIDA’s Principles of Drug Addiction Treatment: A Research-Based Guide.

1. No single treatment is appropriate for all individuals. Matching treatment settings, interventions, and services to each patient’s problems and needs is critical.

2. Treatment needs to be readily available. Treatment applicants can be lost if treatment is not immediately available or readily accessible.

Graph showing 8th 10th and 12th grade use of illicit drugs3. Effective treatment attends to multiple needs of the individual, not just his or her drug use. Treatment must address the individual’s drug use and associated medical, psychological, social, vocational, and legal problems.

4. At different times during treatment, a patient may develop a need for medical services, family therapy, vocational rehabilitation, and social and legal services.

5. Remaining in treatment for an adequate period of time is critical for treatment effectiveness. The time depends on an individual’s needs. For most patients, the threshold of significant improvement is reached at about 3 months in treatment. Additional treatment can produce further progress. Programs should include strategies to prevent patients from leaving treatment prematurely.

6. Individual and/or group counseling and other behavioral therapies are critical components of effective treatment for addiction. In therapy, patients address motivation, build skills to resist drug use, replace drug-using activities with constructive and rewarding nondrug-using activities, and improve problem-solving abilities. Behavioral therapy also facilitates interpersonal relationships.

Graph showing percentage of U.S. Population who have ever used drugs of abuse7. Medications are an important element of treatment for many patients, especially when combined with counseling and other behavioral therapies. Buprenorphine, methadone and levo-alpha-acetylmethodol (LAAM) help persons addicted to opiates stabilize their lives and reduce their drug use. Naltrexone is effective for some opiate addicts and some patients with co-occurring alcohol dependence. Nicotine patches or gum, or an oral medication, such as buproprion, can help persons addicted to nicotine.

8. Addicted or drug-abusing individuals with coexisting mental disorders should have both disorders treated in an integrated way.

9. Medical detoxification is only the first stage of addiction treatment and by itself does little to change long-term drug use. Medical detoxification manages the acute physical symptoms of withdrawal. For some individuals it is a precursor to effective drug addiction treatment.

10. Treatment does not need to be voluntary to be effective. Sanctions or enticements in the family, employment setting, or criminal justice system can significantly increase treatment entry, retention, and success.

11. Possible drug use during treatment must be monitored continuously. Monitoring a patient’s drug and alcohol use during treatment, such as through urinalysis, can help the patient withstand urges to use drugs. Such monitoring also can provide early evidence of drug use so that treatment can be adjusted.

12. Treatment programs should provide assessment for HIV/AIDS, hepatitis B and C, tuberculosis and other infectious diseases, and counseling to help patients modify or change behaviors that place them or others at risk of infection. Counseling can help patients avoid high-risk behavior and help people who are already infected manage their illness.

13. Recovery from drug addiction can be a long-term process and frequently requires multiple episodes of treatment. As with other chronic illnesses, relapses to drug use can occur during or after successful treatment episodes. Participation in self-help support programs during and following treatment often helps maintain abstinence.

Get Adobe Reader
This document also available
in PDF format [212 Kb]

Commonly Abused
Drugs Flyer

Need a drug treatment referral call 1.800.662.4357

See Also:

NIDA’s Publication Series:

Other Web Sites:


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Tuesday, May 5, 2009. The U.S. government's official web portal
  • Share/Save/Bookmark

Next posts » Back to top